| Literature DB >> 34939198 |
Diogo Henrique Kita1,2, Gisele Alves de Andrade1, Juliana Morais Missina3, Kahoana Postal3, Viktor Kalbermatter Boell3, Francielli Sousa Santana3, Ingrid Fatima Zattoni1, Isadora da Silva Zanzarini1, Vivian Rotuno Moure1,4, Fabiane Gomes de Moraes Rego4, Geraldo Picheth4, Emanuel Maltempi de Souza5, David A Mitchell5, Suresh V Ambudkar2, Giovana Gioppo Nunes3, Glaucio Valdameri1,4.
Abstract
A promising strategy to overcome multidrug resistance is the use of inhibitors of ABC drug transporters. For this reason, we evaluated the polyoxovanadates (POVs) [V10 O28 ]6- (V10 ), [H6 V14 O38 (PO4 )]5- (V14 ), [V15 O36 Cl]6- (V15 ) and [V18 O42 I]7- (V18 ) as inhibitors of three major multidrug resistance-linked ABC transporters: P-glycoprotein (P-gp), ABCG2 and MRP1. All of the POVs selectively inhibited P-gp. V10 and V18 were the two most promising compounds, with IC50 values of transport inhibition of 25.4 and 22.7 µm, respectively. Both compounds inhibited P-gp ATPase activity, with the same IC50 value of 1.26 µm. V10 and V18 triggered different conformational changes in the P-gp protein with time-dependent inhibition, which was confirmed using the synthesized salt of V10 with rhodamine B, RhoB-V10 . The hydrophilic nature of POVs supports the hypothesis that these compounds target an unusual ligand-binding site, opening new possibilities in the development of potent modulators of ABC transporters.Entities:
Keywords: ABC transporters; P-glycoprotein; cancer; inhibitors; multidrug resistance; polyoxovanadates
Mesh:
Substances:
Year: 2021 PMID: 34939198 PMCID: PMC9340886 DOI: 10.1002/1873-3468.14265
Source DB: PubMed Journal: FEBS Lett ISSN: 0014-5793 Impact factor: 3.864